CIK 0001824293
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GRI Bio, Inc.
Sign in to watch- Ticker
- GRI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 824369909
- Phone
- +1 619-400-1171
- Business address
- 2223 AVENIDA DE LA PLAYA, SUITE 208, LA JOLLA, CA, 92037
- Former names
- Vallon Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-04 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +3,935 | 3,935 | ||
| 2025-09-18 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +23,605 | 23,605 | ||
| 2025-08-26 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +5,994 | 5,994 | ||
| 2025-08-13 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +4,527 | 4,527 | ||
| 2025-01-23 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +30,297 | $0.69 | $21K | 30,297 |
| 2023-08-10 | Baker David Charles Director | Grant or award · Stock Option (Right to Buy) | +34,483 | $2.90 | $100K | 34,483 |
| 2022-02-15 | Baker David Charles Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +61,000 | $5.63 | $343K | 61,000 |
| 2021-05-14 | Baker David Charles Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-02-12 | Baker David Charles Chief Executive Officer | Other acquisition | +7,843 | $6.40 | $50K | 7,843 |
| 2021-02-12 | Baker David Charles Chief Executive Officer | Purchase | +1,000 | $8.00 | $8K | 8,843 |
Page 1 of 1 · 10 trades